Skip to main content
Scientific Reports logoLink to Scientific Reports
. 2021 Apr 19;11:8831. doi: 10.1038/s41598-021-88629-2

Author Correction: The number of osteoclasts in a biopsy specimen can predict the efficacy of neoadjuvant chemotherapy for primary osteosarcoma

Yoshihiro Araki 1, Norio Yamamoto 1,, Katsuhiro Hayashi 1, Akihiko Takeuchi 1, Shinji Miwa 1, Kentaro Igarashi 1, Takashi Higuchi 1, Kensaku Abe 1, Yuta Taniguchi 1, Hirotaka Yonezawa 1, Sei Morinaga 1, Yohei Asano 1, Hiroko Ikeda 2, Takayuki Nojima 2, Hiroyuki Tsuchiya 1
PMCID: PMC8055875  PMID: 33875768

Correction to: Scientific Reports 10.1038/s41598-020-80504-w, published online 21 January 2021

The original version of this Article contained errors.

Author names Yoshihiro Araki, Norio Yamamoto, Katsuhiro Hayashi, Akihiko Takeuchi, Shinji Miwa, Kentaro Igarashi, Takashi Higuchi, Kensaku Abe, Yuta Taniguchi, Hirotaka Yonezawa, Sei Morinaga, Yohei Asano, Hiroko Ikeda, Takayuki Nojima, Hiroyuki Tsuchiya were incorrectly given as Y. Araki, N. Yamamoto, K. Hayashi, A. Takeuchi, S. Miwa, K. Igarashi, T. Higuchi, K. Abe, Y. Taniguchi, H. Yonezawa, S. Morinaga, Y. Asano, H. Ikeda, T. Nojima, H. Tsuchiya.

In addition, the Article contains a typographical error in the Results section, in the number of years in the ROC curve analyses for the optimal cut-off values.

“The optimal cut-off values were as follows: age, 47 years old (area under the curve [AUC], 0.59); size, 93 mm (AUC, 0.53); number of osteoclasts in the biopsy specimen, 5 (AUC, 0.75), number of courses of DOX as neoadjuvant chemotherapy, 3 (AUC, 0.63); number of courses of CDDP as neoadjuvant chemotherapy, 3 (AUC, 0.65); number of courses of IFO as neoadjuvant chemotherapy, 4 (AUC, 0.51), and number of courses of MTX as neoadjuvant chemotherapy, 1 (AUC, 0.48) (Table 1).”

now reads:

“The optimal cut-off values were as follows: age, 46 years old (area under the curve [AUC], 0.59); size, 93 mm (AUC, 0.53); number of osteoclasts in the biopsy specimen, 5 (AUC, 0.75), number of courses of DOX as neoadjuvant chemotherapy, 3 (AUC, 0.63); number of courses of CDDP as neoadjuvant chemotherapy, 3 (AUC, 0.65); number of courses of IFO as neoadjuvant chemotherapy, 4 (AUC, 0.51), and number of courses of MTX as neoadjuvant chemotherapy, 1 (AUC, 0.48) (Table 1).”

The number of years has been correctly shown in Table 1.

Furthermore, in Table 2, in the subcategory Stage,

“II/IV”

now reads:

“III/IV”

These errors have now been corrected in the PDF and HTML versions of the Article.


Articles from Scientific Reports are provided here courtesy of Nature Publishing Group

RESOURCES